General Electric Company

Chinese Academy of Sciences

Tetra Laval Holdings & Finance S.a.

Shanghai Huahong Grace Semiconductor Manufacturing Corporation

Zhejiang Hisun Pharmaceutical Co., Ltd.

Shanghai Zaiqi Bio-tech Co., Ltd.

Nanjing Pailexing Pharmaceutical Technology Ltd.

Shanghai Dianhua Digital Technology Co., Ltd.

Nio (anhui) Holding Co., Ltd.

Peng Sun

Hui Li

Bo Li

Yi Bu Li

Bin Liu

Jun Hui Liu

Hualiang Jiang

Hua Bai

Bo Zhang

Xin Zhang

Kaixian Chen

Ting Ting Zhang

Gang Yao

Chao Li

Fanbin Wang

Yi Li

Xiaohe Zheng

Xiaoyu Liu

Jia Pan

Jiye Yang

Xuefei Xie

Junjun Xing

Zhijian Xu

Weiliang Zhu

Yingqiu Wu

Yaping Wang

Chong Chen

Xuan Huang

Tongbo Zhang

Yiping Yao

Hongyan Li

Guojun Zheng

Jian Zhang

Aiyuan Liu

Dejie Chen

Heyao Wang

Beibei Tian

An IGBT device and a method for manufacturing it, the device includes a super junction structure that has several N-type pillars and P-type pillars arranged alternately; a cell unit that is located in an N-type epitaxial layer, and the N-type epitaxial layer is located above the N-type substrate; each cell unit includes a trench gate, a P-type body region, and a source region; an N-type carrier injection layer, the N-type carrier injection layer is located in the N-type epitaxial layer, and the N-type carrier injection layer is spaced apart from the N-type substrate by the N-type epitaxial layer; the bottom of the P-type body region is located in the N-type carrier injection layer; and a collector region that is located at the bottom of the N-type substrate.

IGBT device and method of making the same

The present disclosure relates to a crystal form of a key intermediate of a bruton tyrosine kinase (BTK) inhibitor and a method for preparing the crystal form, and belongs to the technical field of medicine. The crystal form is a crystal form II of (R)-1-(1-(tert-butyloxyl)pyrrolidine-3-yl)-3-cyano-4-(4-(2,6-difluorophenoxyl)phenyl)-1H-pyrrole-2-ethyl formate. The obtained crystal form II of (R)-1-(1-(tert-butyloxyl)pyrrolidine-3-yl)-3-cyano-4-(4-(2,6-difluorophenoxyl)phenyl)-1H-pyrrole-2-ethyl formate has good chemical stability and crystal form stability and is convenient for storage and transportation. Meanwhile, the intermediate can be highly purified and a sample with a purity of 99.7% is obtained. The crystal form is important for quality control of a BTK inhibitor (R)-4-amino-1-(1-(butyl-2-alkynyl)pyrrolidine-3-yl)-3-(4-(2,6-difluorophenoxyl)phen yl)-1,6-dihydro-7H-pyrrolo[2,3-d]pyridazin-7-one, has a simple preparation process and is suitable for industrial production.

Crystal form of key intermediate of bruton tyrosine kinase (BTK) inhibitor and preparation method thereof

Disclosed is a(Nakai) Kupr. extract, specifically compounds I and II, a preparation method for same, and a use thereof in preparing a medicament for blood glucose decease, blood lipids decrease, weight loss, and kidney disease treatment or a method for treatment of said diseases, and a composition containing the extract.

extract, preparation method for same, and use thereof in sugar reduction, weight loss, and lipid reduction

A smart puzzle cube having prompting and recording functions includes at least four cubes (), a central sphere body (), and at least one conductive connector (). The cubes () and the central sphere body () are securely connected by the conductive connector () via a mechanical connection, the cubes () are structurally connected to each other and rotatable, and puzzle cube layers formed by the cubes () rotate in both directions without limit. The conductive connector () includes a rotation detection module () that detects rotation directions and angles of the puzzle cube layers.

Smart puzzle cube having prompting and recording functions

Phenyl propanoic acid compounds having activating effect on peroxisome proliferator-activated receptors (PPAR&#x3b1;,&#x3b4;,&#x3b3;) and a preparation method and uses thereof are provided in the present invention. The compounds can be used for treating or preventing diseases associated with peroxisome proliferator-activated receptors (PPAR&#x3b1;,&#x3b4;,&#x3b3;).

Compounds having activating effect on subtypes of peroxisome proliferator-activated receptors and its preparation method and uses

The present invention relates to a sterile filling system, and specifically relates to a sterile filling system for on-line particle adding comprising a filling system, characterized in that it further comprises a system for on-line particle adding. The filling system comprises a first AP valve bank and an injection pipe, the first AP valve bank and the injection pipe being in connection with each other; and the system for on-line particle adding comprises a second AP valve bank, the second AP valve bank being in connection with the injection pipe. The present invention can achieve the object of addition of solid particles during the production of liquid product, and ensure that the finished product will meet the requirement for sterility.

Sterile filling system for on-line particle adding

Ballasts are presented with improved end-of-life (EOL) detection of lamp DC voltage components and protection circuits to facilitate user maintenance and extend lamp life using selective dimming with preheating when EOL conditions are detected.

Ballast with end-of-life protection for one or more lamps

Growing community of inventors

Shanghai, China

Peng Sun